Navigation Links
Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
Date:5/19/2008

SAN DIEGO, May 19 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of therapeutic oxygen transport agents today announced that it has completed enrollment in the second Phase III trial of its lead product, Hemospan(R).

Sangart expects the top line results from this trial to be available in the second half of 2008.

The 370-patient randomized, double-blind, controlled Phase III study was conducted at 18 clinical sites in six European countries. Together with another Phase III study completed in March, the trials were designed to evaluate the safety and efficacy of Hemospan for preventing and treating hemodynamic instability, particularly hypotension, or low blood pressure, during primary hip replacement surgery.

Dr. Robert Winslow, Chairman, President and CEO of Sangart, commented, "The completed enrollment in this second Phase III trial represents another significant milestone for Sangart as we advance the development of Hemospan."

No similar oxygen transport agents are currently on the market in Europe or the United States. Extensive preclinical efficacy studies and earlier clinical trials indicate that Hemospan's novel oxygen delivery mechanism has the potential to enhance oxygenation of ischemic tissues and may provide a safe and effective alternative to blood transfusion, especially when blood is not immediately available.

About Sangart

Sangart is a privately held San Diego-based biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as therapeutic oxygen transport agents and potential alternatives to blood transfusions.

Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-f
'/>"/>

SOURCE Sangart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
2. Lilly Completes Final Phase of Its Indianapolis Biotechnology Complex
3. China-Biotics, Inc. Completes Foundation for Its New Plant
4. Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc.
5. EUSA Pharma Completes Acquisition Of Cytogen Corporation
6. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
7. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
10. Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
11. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-... ARNA ) announced today that the company is sch... Health Care Conference on December 1, 2009 at 11:...he New York Palace Hotel in New York City. Jack Li... is scheduled to provide an overview of the compan...
(Date:11/24/2009)... , BOZEN, Italy, November 24 /PRNewsw...s formed a new Canadian joint venture with a group...to-based company will operate under the,name Healt...and support,Health Robotics, i.v. Room of the Futu...ct offerings i.v.STATION(TM), i.v.SOFT(TM), and OM...
(Date:11/24/2009)... Chemical Abstracts Service ...reports that China,s patent office is now the worl...ons in chemistry. China trailed Japan,s patent off...(WIPO), and the United States Patent and Trademark... the USPTO in 2005, WIPO in 2006, and exceeded Jap...
(Date:11/23/2009)...SALT LAKE CITY, Nov. 23, 2009 In a provocative ne...t rising carbon dioxide emissions the major cause...e world,s economy collapses or society builds the .... , "It looks unlikely that there will be any s...ved acceleration in carbon dioxide emission rates,...
Breaking Biology Technology:Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 3China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4
... Shows Clear Promise as a Stable Long-acting Antic...rders., ThromboGenics NV (Euronext Brussels:THR),...ye disease, announced that the results of the,firs... at the prestigious,American Society of Hematology.... TB-402 is being co-developed in collaboration wi...
... Inc.,(Amex: TTG ), a leading manufacturer of ste...allograft) and animal (xenograft) tissue, today an...fourth quarter ended September,30, 2007., Summar..., -- Total fiscal year 2007 revenues increased 4... fiscal year 2007; -- Sales of spine products in...
...ion and GE,Healthcare Financial Services have prov...cured loan to Astex Therapeutics Limited. This rep...to a biotechnology company in,Europe., Astex Ther...he largest,privately-held biotech companies in the...t of small molecule drugs in areas of unmet medica...
Other Biology Technology:ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 2Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 3Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 4Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 5Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 6Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 7Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 8Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 9Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results 10Oxford Finance Corporation and GE Healthcare Financial Services Reaffirm Commitment to Biotech Sector in Europe 2
(Date:11/24/2009)... thousands of years it has been prescribed by trad...ents from headaches and stomach pain to fever and ...castle University have been able to scientifically...enata otherwise known as Brazilian mint. , Test...team led by researcher Graciela Rocha was able to ...
(Date:11/24/2009)...nts that keep weakened and flabby arteries from co... months, those stents are no longer needed -- once...ssary. Previously, doctors had no choice but to le...el Aviv University,s Department of Biomedical Engi...latform that carries drugs where they,re needed, t...
(Date:11/24/2009)...ATON ROUGE Antarctica has long held secrets of th...til recently, there has been very little informati...th miles of ice for millions of years. Now, a team...LSU have been funded to the tune of $10 million d... to get to the bottom of things literally. These ...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2A coating for life 2LSU gets to the bottom of things -- in Antarctica 2Race Insurance May Affect Testing of Kids in ER 59679 1Race Insurance May Affect Testing of Kids in ER 59679 2Transplant May Treat Metabolic Disorders in Womb 59677 1Transplant May Treat Metabolic Disorders in Womb 59677 2Chicago Veterinary Emergency Services Goes 24 7 for Emergency Care 59672 1Chicago Veterinary Emergency Services Goes 24 7 for Emergency Care 59672 2
...28, 2009 Congressman James McGovern, D-Massachuse... (NIH) awards for two researchers at Worcester Pol...ing Center at Gateway Park. , Glenn Gaudette, PhD... WPI, will receive $403,000 over two years to adva...to restore function to damaged hearts. Terri Cames...
...e devastating effects on endangered species, but n...tion of a population of bighorn sheep. , The effe...rn sheep can be mathematically predicted, as descr...000 Biology members Barry Brook and Lochran Traill...studied a population of bighorn sheep introduced t...
...research team say they,ve made a big improvement i...and other biological materials one that may be a ... , It consists of a piece of synthetic antibody a...ical base, immersed in liquid. , If the protein t...will bind to these antibodies, immediately creatin...
Other Biology News:NIH funds work at WPI on regenerating heart tissue and preventing urinary tract infections 2A quicker, cheaper SARS virus detector -- one easily customizable for other targets 2
Chicken Anti-Human Quinolinate phosphoribosyltransferase Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.
Anti-J Chain Monoclonal Antibody, Unconjugated, Clone M19/9J from CHEMICON
Tissue Stat from Biomeda Corporation
Clarion Mounting Medium - 6X100 ml from Biomeda Corporation
Biology Products: